Exclusive license agreement

Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting...

Grant to develop a new innovative product

The Danish Innovation Fund has granted Solural Pharma 1.5 mio DKK for together with Contera Pharma ApS (part of Bukwang Pharmaceuticals Co Ltd) , Dr. Sandra Klein, the University of Greifswald and Erweka Gmbh, to develop a new innovative product for the treatment of...